Ampio Pharmaceuticals Reports First-Quarter Financial Results
Ampio Pharmaceuticals, Inc. (AMPE) reported a net loss of $5.6 million for Q1 2022, compared to $3.7 million in Q1 2021. Research and development expenses increased to $3.7 million from $2.3 million in the previous year, primarily due to clinical trials and salaries. General and administrative expenses rose to $3.3 million from $1.5 million, driven by higher salaries and stock-based compensation. Cash and cash equivalents decreased to $28.8 million from $33.9 million, with sufficient liquidity expected to fund operations into H2 2023.
- Sufficient liquidity expected to fund operations into the second half of 2023.
- Net loss increased to $5.6 million from $3.7 million year-over-year.
- Research and development expenses rose, indicating increased financial pressure.
- General and administrative expenses significantly increased, impacting overall cash flow.
- Cash and cash equivalents decreased by $5.1 million, indicating cash burn.
ENGLEWOOD, Colo., May 16, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today reported financial results for the first quarter ended March 31, 2022.
First Quarter Financial Results
- Net Loss: Net loss was
$5.6 million for the first quarter of 2022 compared to net loss of$3.7 million for the first quarter of 2021. Further details on these variances are below. - R&D Expenses: Research and development expenses were
$3.7 million for the first quarter of 2022 compared to$2.3 million for the first quarter of 2021. The primary drivers of the increase were increases in (i) clinical trial and sponsored research expenses and (ii) salaries and professional fees. - G&A Expenses: General and administrative expenses were
$3.3 million for the first quarter of 2022 compared to$1.5 million for the first quarter of 2021. The primary drivers of the increase were increases in (i) salaries and professional fees and (ii) non-cash stock-based compensation expense. - Cash Position / Liquidity: Cash and cash equivalents on March 31, 2022, totaled
$28.8 million , compared to$33.9 million as of December 31, 2021. The decrease of$5.1 million is primarily attributable to cash required to fund business operations. Based on our current cash position and projection of operating expenses and capital expenditures, we believe that we will have sufficient liquidity to fund operations into the second half of 2023.
Further details on First Quarter 2022 Financials are included below:
AMPIO PHARMACEUTICALS, INC. | ||||||
March 31, | December 31, | |||||
2022 | 2021 | |||||
Assets | ||||||
Current assets | ||||||
Cash and cash equivalents | $ | 28,837,000 | $ | 33,892,000 | ||
Prepaid expenses and other | 1,070,000 | 1,740,000 | ||||
Total current assets | 29,907,000 | 35,632,000 | ||||
Fixed assets, net | 2,302,000 | 2,564,000 | ||||
Right-of-use asset, net | 577,000 | 629,000 | ||||
Total assets | $ | 32,786,000 | $ | 38,825,000 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities | ||||||
Accounts payable and accrued expenses | $ | 5,208,000 | $ | 4,811,000 | ||
Lease liability-current portion | 318,000 | 311,000 | ||||
Total current liabilities | 5,526,000 | 5,122,000 | ||||
Lease liability-long-term | 533,000 | 614,000 | ||||
Warrant derivative liability | 4,474,000 | 5,805,000 | ||||
Total liabilities | 10,533,000 | 11,541,000 | ||||
Commitments and contingencies (Note 5) | ||||||
Stockholders' equity | ||||||
Preferred Stock, par value | — | — | ||||
Common Stock, par value | 23,000 | 23,000 | ||||
Additional paid-in capital | 245,468,000 | 244,863,000 | ||||
Accumulated deficit | (223,238,000) | (217,602,000) | ||||
Total stockholders' equity | 22,253,000 | 27,284,000 | ||||
Total liabilities and stockholders' equity | $ | 32,786,000 | $ | 38,825,000 | ||
AMPIO PHARMACEUTICALS, INC. | ||||||
Three Months Ended March 31, | ||||||
2022 | 2021 | |||||
Operating expenses | ||||||
Research and development | $ | 3,687,000 | $ | 2,296,000 | ||
General and administrative | 3,283,000 | 1,523,000 | ||||
Total operating expenses | 6,970,000 | 3,819,000 | ||||
Other income | ||||||
Interest income | 3,000 | 1,000 | ||||
Derivative gain | 1,331,000 | 151,000 | ||||
Total other income | 1,334,000 | 152,000 | ||||
Net loss | $ | (5,636,000) | $ | (3,667,000) | ||
Net loss per common share: | ||||||
Basic | $ | (0.02) | $ | (0.02) | ||
Diluted | $ | (0.03) | $ | (0.02) | ||
Weighted average number of common shares outstanding: | ||||||
Basic | 226,083,328 | 195,387,047 | ||||
Diluted | 226,110,693 | 200,752,267 | ||||
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies for the potential treatment of multiple inflammatory conditions (e.g., osteoarthritis of the knee (OAK) and other articular joints). Ampio's lead drug is Ampion™.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, words such as "may," "will," "expect," "believe," "anticipate," or "estimate" or comparable terminology are intended to identify forward-looking statements. Forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements.
Such forward-looking statements include, for example, statements about Ampio's projection of operating expenses, capital expenditures and future liquidity. The risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements include the risk factors described in the Ampio's Annual Report on Form 10-K for the year ended December 31, 2021, and other factors set forth in Ampio's filings with the Securities and Exchange Commission, including Ampio's Quarterly Report on Form 10-Q for the quarter ended March 31, 2022.
The forward-looking statements in this press release speak only as of the date of this press release. Except as required by law, Ampio assumes no obligation to update or revise these forward-looking statements for any reason, except as required by law.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
info@ampiopharma.com
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-reports-first-quarter-financial-results-301548272.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
What were Ampio Pharmaceuticals' financial results for Q1 2022?
How are Ampio Pharmaceuticals' R&D expenses trending?
What is the cash position of Ampio Pharmaceuticals as of March 31, 2022?
What is the expected liquidity outlook for Ampio Pharmaceuticals?
How have general and administrative expenses changed for Ampio Pharmaceuticals?
